SK bioscience and Thailand’s GPO enter MoU to boost vaccine response

06 Jul 2023
www.pharmaceutical-technology.com
Vaccine
SK bioscience and Thailand’s GPO enter MoU to boost vaccine response
Preview
Source: Pharmaceutical Technology
(From left) Thailand Permanent Secretary of the Ministry of Public Health Dr Opas Karnkawinpong, GPO managing director Dr Mingkwan Suphannaphong, SK bioscience, CEO Jaeyong Ahn and Embassy of the Republic of Korea in Thailand Charge d’affaires ad interim Joyoung Jeon at the MoU at the Ministry of Public Health of Thailand. Credit: SK bioscience.
South Korea-based SK bioscience and the Thailand state-owned pharmaceutical company the Government Pharmaceutical Organisation (GPO) have entered a memorandum of understanding (MoU) to bolster vaccine infrastructure in Thailand.
The deal will enhance the country’s pandemic response system, aiming to produce Thailand’s vaccines locally. It will then be expanded to the wider southeast Asian region.
Recommended Reports
SK bioscience and Thailand’s GPO enter MoU to boost vaccine response
Preview
Source: Pharmaceutical Technology
ReportsClinical Trials - The Expanding Landscape of Regenerative Medicine GlobalData
SK bioscience and Thailand’s GPO enter MoU to boost vaccine response
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Recombinant viral vector-based medicinal preparations GlobalData
View allCompanies IntelligenceSK IncMOU S.A.The Peter Doherty Institute for Infection and ImmunityView all
The two companies will support vaccine development and manufacturing capabilities in Thailand, working together closely in the mid-to-long-term to support the country as a vaccine hub in southeast Asia.
SK bioscience will transfer its cell culture-based influenza vaccine’s production and manufacturing technology to the GPO’s facility.
Following this technology transfer, SK bioscience will provide the vaccine’s processes to the Thai company, which will seek marketing authorisation from the regulators.
The vaccines produced will be used for the national vaccination drive in Thailand.
GPO managing director Dr Mingkwan Suphannaphong stated: “A MoU-signing ceremony between GPO and SK bioscience today substantially contributes to a collaboration on manufacturing the cell-culture based influenza vaccine locally in Thailand, namely the trivalent and quadrivalent inactivated influenza vaccines.
“The drug substance bulk produced by SK will be initially delivered to GPO prior to making the drug products.”
In June 2023, SK bioscience and the Peter Doherty Institute for Infection and ImmunityInfection and Immunity entered a research partnership to develop a next-generation influenza vaccine.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.